Exclusive Agreement for Oncology Supportive Care Product MISSISSAUGA, Ontario, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive Distribution Agreement with a European partner for a product that is used in oncology supportive care. The product has been marketed in Europe, USA and several other markets around the world to help cancer patients with certain side effects of their treatment. BioSyent anticipates launching the product in Canada in late 2023, pending regulatory approval.
“We are pleased to add this new product to our growing portfolio which provides us with an opportunity to not only grow our top line revenue but also to enter a new therapeutic area of oncology supportive care,” said Ren Goehrum, President and CEO of BioSyent. “This oncology supportive care product aligns with our strategic objectives of growth, portfolio diversification, and corporate longevity by bringing products to Canada that are unique, differentiated and treat unmet medical needs.”